Metabolic switching of BILR 355 in the presence of ritonavir. I. Identifying an unexpected disproportionate human metabolite

Drug Metabolism and Disposition

Volumn 40, Issue 6, 2012, Pages 1122-1129

  Li, Yongmei ^a   Lai, W George ^a,b   Whitcher Johnstone, Andrea ^a   Busacca, Carl A ^a   Eriksson, Magnus C ^a   Lorenz, Jon C ^a   Tweedie, Donald J ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^b EISAI RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 ETHYL 5,11 DIHYDRO 5 METHYL 8 [2 [(1 OXIDO 4 QUINOLINYL)OXY]ETHYL] 6H DIPYRIDO[3,2 B:2',3' E][1,4]DIAZEPIN 6 ONE; BILR 355; BILR 516; CYTOCHROME P450 3A4; DRUG METABOLITE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RITONAVIR; UNCLASSIFIED DRUG;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MICHAELIS MENTEN KINETICS; NONHUMAN; NONLINEAR SYSTEM; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY;

AZEPINES; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; HUMANS; MALE; MICROSOMES, LIVER; PYRIDINES; RITONAVIR; RNA-DIRECTED DNA POLYMERASE;

HUMAN ECHOVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84862109777     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.044354     Document Type: Article

References (21)

1. Bonneau P, Robinson PA, Duan J, Doyon L, Simoneau B, Yoakim C, Garneau M, Bos M, Cordingley M, Brenner B, Spira B, Wainberg M, Huang F, Drda K, Ballow C, Koenen-Bergmann M, and Mayers D (2005) Antiviral characterization and human experience with BILR 355 BS, a novel next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with a broad anti HIV-1 profile. Proceedings of the 12th Conference on Retroviruses and Opportunistic Infections; 2005 Feb 22-25; Boston, MA. Poster 558.
2. Boone LR (2006) Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors. Curr Opin Investig Drugs 7:128-135.
3. Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332. (Pubitemid 27169077)
4. Chauret N, Gauthier A, Martin J, and Nicoll-Griffith DA (1997) In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 25:1130-1136. (Pubitemid 27446582)
5. Davies B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095. (Pubitemid 23211439)
6. de Béthune MP (2010) Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009). Antiviral Res 85:75-90.
7. De Clercq E (1998) The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 38:153-179.
8. De Clercq E (2004) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 1:44-64.
9. European Medicines Agency (2009) ICH topic M3 (R2) non-clinical safety studies for the conduct of human clinical trials and marketing authorization for pharmaceuticals. European Medicines Agency, London, UK.
10. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, et al. (2008) Antiretroviral treatment of adult HIV infection: 2008 recommendations of the international AIDS society-USA panel. JAMA 300:555-570.
11. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, and Montaner JS (1998) Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454. (Pubitemid 28082255)
12. Houston JB (1994) Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 47:1469-1479.
13. Huang F, Drda K, MacGregor TR, Scherer J, Rowland L, Nguyen T, Ballow C, Castles M, and Robinson P (2009) Pharmacokinetics of BILR 355 after multiple oral doses coadministered with a low dose of ritonavir. Antimicrob Agents Chemother 53:95-103.
14. Huang F, Koenen-Bergmann M, Macgregor TR, Ring A, Hattox S, and Robinson P (2008) Pharmacokinetic and safety evaluation of BILR 355, a second-generation nonnucleoside reverse transcriptase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 52:4300-4307.
15. Hull MW and Montaner JS (2011) Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med 43:375-388.
16. Li Y, Xu J, Lai WG, Whitcher-Johnstone A, and Tweedie DJ (2012) Metabolic switching of BILR 355 in the presence of ritonavir. II. Uncovering novel contributions by gut bacteria and aldehyde oxidase. Drug Metab Dispos 40:1130-1137.
17. Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F, and HIV 2020 Project (2010) The future of antiretroviral therapy: challenges and needs. J Antimicrob Chemother 65:827-835.
18. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 283:46-58. (Pubitemid 27438945)
19. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, and Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860. (Pubitemid 28135961)
20. Pang KS and Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625-653. (Pubitemid 8253670)
21. U.S. Food and Drug Administration (2008) Guidance for Industry: Safety Testing of Drug Metabolites. Center for Drug Evaluation and Research, U.S. Food and Drug Administration, U.S. Department of Health and Human Services, Rockville, MD.